Data hints at new indication in the offing for Ofev

Boehringer Ingelheim’s Ofev (nintedanib) had sales of $1.2 billion last year, with the drug becoming an important medicine to treat people with the lung disease idiopathic pulmonary fibrosis (IPF).

These sales could spiral further as it could be approved in another indication in the respiratory space, if Phase III data presented on Monday at the American Thoracic Society (ATS) International Conference in Dallas is anything to go by.

The data, which has also been published in the New England Journal of Medicine, is from the SENSCIS study in systemic sclerosis-associated interstitial lung disease (ILD).